-
Egypt and Syria Sign Agreement to Restore Direct Flights After 14-Year Hiatus
-
Professor Shahida Moosa Pioneers Medical Genomics in South Africa Amid Testing Shortages
-
Van Gogh’s ‘Châtaigniers en Fleurs’ Sets $285m Record at Sotheby’s
-
Texas Marijuana Decriminalization Faces Uncertain Future Under New Attorney General
-
Anthropic Sets Record $81.3 Billion IPO Valuing AI Firm at $1.5 Trillion
-
Early Black Friday Laptop Deals: MacBook Neo, IdeaPad Slim 5x, and Surface Laptop Prices Drop
-
eThekwini Faces R6.5bn Flood Claim from Toyota’s Insurer
-
2026 East Bay Nosh Awards Voting Opens for Food and Drink Favorites
-
Guanajuato Silver Reports Q3 Operating and Financial Results
-
Skilled Nursing Facilities Face 2027 Revenue Cycle Reckoning as Payer Burdens Reshape Admissions and Outsourcing
-
Golden Minerals Completes Drilling Desierto, Argentina
-
Gamma Resources Announces Expansion of Mesa Arc Uranium Project in New Mexico to 4,760 Acres, Completes Radon Flux Baseline Survey
-
Trustpoint Xposure Completes More Than 200 AI Visibility Audits Across Professional Services
-
NoHo, Inc. Acquires Four Placer Gold Claims in Clark County, Nevada from Gold Stake Mining Inc.
-
IRS Shuts Down FIRE Today: What Information Return Filers Need to Know Before the 2027 Filing Season
-
First Canadian Graphite Reports 43.9% Graphitic Carbon Sample and Encouraging Coarse-Flake Characteristics at Zone 13 at Lac Guéret South
-
LASE to Premiere Quantum Bullet(TM) at Counter UAS Technology Conference in Washington, D.C.
-
American Critical Minerals Reports High Grade Potash Intersection of 6.55m Grading 38.51 wt.% KCl at its Green River Project, Utah
-
Hemogenyx Pharmaceuticals PLC - Chairman Receives Prestigious Award
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 19
-
Bob's Watches Founder Paul Altieri Unveils Private Collection of Vintage Rolex Watches in New Book, "NOT FOR SALE"
-
Making the Most of a Long Weekend Without Leaving Town
-
Helio Corporation Engages CORE IR to Provide Investor Relations, Capital Markets Advisory and Media Relations Services
-
Greene Concepts Connects Consumer Needs with Manufacturing Strategy
-
Karbon-X (OTCQB:KARX) Enters California's Multi-Billion-Dollar Compliance Carbon Market Following CITSS Approval
-
Valion Bio Welcomes Former U.S. Army Regulatory Leader and Biotech CEO Dr. Armand Balboni as Advisor in Run-up to Entolimod Therapeutic Efficacy Data Readout
-
multiQure Begins Manufacturing Phase of MQ-201 Gene Therapy for First Huntington's Disease Patients - U.S.-Based Andelyn Biosciences Selected as Manufacturing Partner
-
Arrive AI Eliminates All Debt Through Preferred Equity Exchange
-
QNX Brings Physical AI and Next-Generation Software-Defined Vehicle Innovation to CES 2027
-
More Than Half of Teen AI Chatbot Users Use Them Daily, and 46% Say It Feels Like Talking to a Human, New Family Online Safety Institute Research Finds
-
MicroVision and Blue-Band to Support $3 Million Federally Funded Intelligent Transportation Initiative in Louisville, Kentucky
-
The 2026 MDaudit Annual Benchmark Report Spotlights AI's Impact on Financial Risk as Payer Denials and Audits Continue an Upward Trajectory
-
Metano Emerges From Stealth to Unify AI Agent Security Across the Enterprise
-
Lumber's Union CBA Agent Launches in Sage Agent Marketplace to Help Simplify Union Payroll Compliance
-
ATWEC Technologies, Inc. (OTCID: ATWT) Engages Michael Gillespie & Associates, PLLC to Audit Fiscal 2026 and 2025 Consolidated Financial Statements and Changes Fiscal Year End to October 31
-
Anti-Bullying Week: Five Warning Signs Parents Should Monitor
Drug claims overshadow Musk's Oval Office farewell
Elon Musk faced accusations Friday that he used so much ketamine on the 2024 campaign trail that he developed bladder problems, as the billionaire prepared to give a farewell press conference with Donald Trump.
A New York Times report that Musk's drug use had caused concerns was published just hours before he was to appear with Trump in the White House on his last day as the US government's cost cutter-in-chief.
The newspaper said the world's richest man also took ecstasy and mushrooms and traveled with a pill box last year, adding that it was not known whether Musk also took drugs while heading the so-called Department of Government Efficiency (DOGE).
The South African-born tech tycoon, the biggest donor to Trump's 2024 election campaign, told people that ketamine, an anesthetic that can cause dissociation, had affected his bladder, the NYT added, noting that it was a known effect of long-term use.
Space X and Tesla boss Musk did not immediately comment, but the White House played down the report.
Asked if he was concerned about alleged drug use by Musk, Trump's Deputy Chief of Staff Stephen Miller told reporters: "The drugs that we're concerned about are the drugs running across the southern border."
Trump's administration has pledged to crack down on migration and the flow of the opiate fentanyl from Mexico.
Miller separately told CNN when asked if Musk had been drug tested while working for the White House: "You'll have the opportunity to ask Elon all the questions you want today yourself."
Musk has previously admitted to taking ketamine, saying he was prescribed it to treat a "negative frame of mind" and suggesting his use of drugs benefited his work.
- 'Terrific' -
The latest claims will add to the challenge of putting a positive spin on Musk's departure after just four turbulent months.
Trump has announced a joint press conference in the Oval Office at 1.30 pm (1730 GMT). The president praised the "terrific" Musk on Thursday and insisted that his influence would continue despite him returning to his companies.
"This will be his last day, but not really, because he will, always, be with us, helping all the way," Trump said on his Truth Social network.
But the news conference will be a far cry from Musk's first appearance in the Oval Office in February, when he brought his young son with him and outshone even the attention-seeking president himself.
At the time the 53-year-old was almost inseparable from Trump, glued to his side on Air Force One, Marine One, in the White House and at Trump's Mar-a-Lago resort in Florida.
Yet Musk is now leaving Trump's administration under a cloud, after admitting disillusionment with his role and criticizing the Republican president's spending plans.
- 'Disappointed' -
The right-wing magnate's DOGE led an ideologically-driven rampage through the federal government, with its young "tech bros" slashing tens of thousands of jobs.
It has also shuttered whole departments including the US Agency for International Development (USAID), leading to huge cuts in foreign aid that critics say will hit some of the world's poorest people and help US rivals.
But DOGE's achievements fell far short of Musk's boasts when he blazed into Washington brandishing a chainsaw at a conservative event and bragged that it would be easy to cut two trillion dollars.
In reality, the independent "Doge Tracker" site has counted just $12 billion in savings while the Atlantic magazine put it far lower, at $2 billion.
Musk's "move fast and break things" mantra was also at odds with some of his cabinet colleagues, and he said earlier this week that he was "disappointed" in Trump's planned mega tax and spending bill as it undermined DOGE's cuts.
Musk's companies, meanwhile, have suffered.
Tesla shareholders called for him to return to work as sales slumped and protests targeted the electric vehicle maker, while Space X had a series of fiery rocket failures.
O.Johnson--AMWN